Thanks BDZ....although the adjective "great" I don't think really applies, but I do think its at least competent writing :-)

Ironically, using the criteria I outlined...looking for small cap spec biotechs that haven't had a run in the past couple of years....RVX did already have a pretty big run last year, not the 10 bagger type I reference ($1 to $10 or $10 to $100) but a 600% (or so) climb from 50 cents to $3 is nothing to sneeze at.

The difficulty here is that...

Where is the incentive to elevate the PPS? RVX is pretty much fully funded for the BOM trial, so in the near term...whether the PPS is $1 or $1.5 or $5 it doesn't make much difference in terms of the company having the money they need to pay expenses like salaries, rent and the like.

The fact that they're being pretty damn quiet on the news front, it has me cautiously optimistic that those in the know....that they are at least confident in the outcome of the trial.